文献速递肿瘤 PET/CT放射性药物与辐射防护

2-FDG PET能否准确反映体内葡萄糖利用?

Does 2-FDG PET Accurately Reflect Quantitative In Vivo Glucose Utilization?
PubMed 文献 · J Nucl Med · 2019-11-01

本文指出2-FDG PET虽广泛用于临床监测葡萄糖代谢,但存在关键局限:集总常数(LC)并非恒定,且在肿瘤不同阶段可能变化;2-FDG仅反映GLUT介导的转运,不反映SGLT介导的葡萄糖利用;建议联合Me-4FDG以更全面评估葡萄糖利用。

要点

  • LC并非恒定,疾病治疗前后可能变化,影响定量准确性。
  • 2-FDG仅反映GLUT转运,不反映SGLT介导的葡萄糖利用。
  • 肿瘤中LC变异显著,可能影响预后判断和治疗监测。

核心结论

  • 2-FDG PET的LC并非恒定,尤其在肿瘤不同阶段变异显著,影响定量葡萄糖利用的准确性。
  • 2-FDG仅反映GLUT介导的转运,不反映SGLT介导的葡萄糖利用。
  • 联合2-FDG与Me-4FDG可更全面评估GLUT和SGLT介导的葡萄糖利用。

研究设计与样本

  • 本文为综述性报告,未报告系统检索范围或样本量。

主要发现

  • LC在特定组织中并非恒定,疾病治疗前后可能变化。
  • 2-FDG是GLUT的良好底物,但不是SGLT的底物。
  • SGLT介导的葡萄糖转运可用Me-4FDG评估。
  • 肿瘤中LC变异尤其显著,尤其在不同癌症发展阶段。

关键数值与推荐

  • 2-FDG的LC用于定量体内葡萄糖利用,但不应期望其保持恒定。
  • SGLT介导的葡萄糖转运可用α-甲基-4-脱氧-4-18F-氟-D-吡喃葡萄糖苷(Me-4FDG)评估。

临床怎么用

  • 使用2-FDG PET推断葡萄糖代谢时,需认识其作为代谢率替代指标的潜在局限。
  • 即使仅用SUV参数,也需注意LC变异,尤其疾病进展时。
  • 可考虑联合2-FDG与Me-4FDG以更全面评估葡萄糖利用。

局限性

  • 本文为报告性文章,未报告系统检索策略或原始研究数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

2-Deoxy-2-18F-fluoro-d-glucose (2-FDG) with PET is undeniably useful in the clinic, being able, among other uses, to monitor change over time using the 2-FDG SUV metric. This report suggests some potentially serious caveats for this and related roles for 2-FDG PET. Most critical is the assumption that there is an exact proportionality between glucose metabolism and 2-FDG metabolism, called the lumped constant, or LC. This report describes that LC is not constant for a specific tissue and may be variable before and after disease treatment. The purpose of this work is not to deny the clinical value of 2-FDG PET; it is a reminder that when one extends the use of an appropriately qualified imaging method, new observations may arise and further validation would be necessary. The current understanding of glucose-based energetics in vivo is based on the quantification of glucose metabolic rates with 2-FDG PET, a method that permits the noninvasive assessment of various human disorders. However, 2-FDG is a good substrate only for facilitated-glucose transporters (GLUTs), not for sodium-dependent glucose cotransporters (SGLTs), which have recently been shown to be distributed in multiple human tissues. Thus, the GLUT-mediated in vivo glucose utilization measured by 2-FDG PET would be masked to the potentially substantial role of functional SGLTs in glucose transport and use. Therefore, under these circumstances, the 2-FDG LC used to quantify in vivo glucose utilization should not be expected to remain constant. 2-FDG LC variations have been especially significant in tumors, particularly at different stages of cancer development, affecting the accuracy of quantitative glucose measures and potentially limiting the prognostic value of 2-FDG, as well as its accuracy in monitoring treatments. SGLT-mediated glucose transport can be estimated using α-methyl-4-deoxy-4-18F-fluoro-d-glucopyranoside (Me-4FDG). Using both 2-FDG and Me-4FDG should provide a more complete picture of glucose utilization via both GLUT and SGLT transporters in health and disease states. Given the widespread use of 2-FDG PET to infer glucose metabolism, it is relevant to appreciate the potential limitations of 2-FDG as a surrogate for glucose metabolic rate and the potential reasons for variability in LC. Even when the readout for the 2-FDG PET study is only an SUV parameter, variability in LC is important, particularly if it changes over the course of disease progression (e.g., an evolving tumor).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Barrio JR, Huang SC, Satyamurthy N, et al. Does 2-FDG PET Accurately Reflect Quantitative In Vivo Glucose Utilization? J Nucl Med. 2019. PMID: 31676728. doi:10.2967/jnumed.119.237446

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。